Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study

被引:22
|
作者
Choe, Hun Jee [1 ,2 ]
Rhee, Eun-Jung [3 ]
Won, Jong Chul [4 ]
Park, Kyong Soo [1 ,2 ]
Lee, Won-Young [3 ]
Cho, Young Min [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Endocrinol & Metab, Dept Internal Med,Sch Med, Seoul, South Korea
[4] Inje Univ, Sanggye Paik Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
关键词
SENSING TECHNOLOGY; REAL-TIME; NUTRITION; RECOMMENDATIONS; MULTICENTER; MANAGEMENT; ADULTS; CARE;
D O I
10.2337/dc22-0764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring (isCGM) in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted a 12-week, open-label, randomized controlled trial. A total of 126 participants were 1:1 randomized to either the intervention group (structured education + isCGM) or the control group (standard care with blood glucose monitoring). The Self-Evaluation Of Unhealthy foods by Looking at postprandial glucose (SEOUL) algorithm was developed and applied to aid structured education in guiding patients to follow healthy eating behavior depending on the postprandial glycemic response. The primary end point was the change in HbA(1c) level from baseline. RESULTS Implementation of the SEOUL algorithm with isCGM was associated with greater improvement in HbA(1c) than with standard care (risk-adjusted difference -0.50%, 95% CI -0.74 to -0.26, P < 0.001). Participants in the intervention group had a greater reduction in fasting blood glucose and body weight (-16.5 mg/dL, 95% CI -30.0 to -3.0, P = 0.017; -1.5 kg, 95% CI -2.7 to -0.3, P = 0.013, respectively). The score sum for the Korean version of the revised Summary of Diabetes Self-Care Activities Questionnaire increased in both groups but to a greater extent in the intervention group (mean difference 4.8, 95% CI 1.7-8.0, P = 0.003). No severe hyperglycemia or hypoglycemia was reported in either group of patients. CONCLUSIONS Patient-driven lifestyle modification primarily focused on eating behavior using isCGM effectively lowered HbA(1c) levels in patients with T2D.
引用
收藏
页码:2224 / 2230
页数:7
相关论文
共 45 条
  • [31] Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
    Ferrannini, Ele
    Berk, Andreas
    Hantel, Stefan
    Pinnetti, Sabine
    Hach, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2013, 36 (12) : 4015 - 4021
  • [32] Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study
    Niwaha, Anxious J.
    Rodgers, Lauren R.
    Carr, Alice L. J.
    Balungi, Priscilla A.
    Mwebaze, Raymond
    Hattersley, Andrew T.
    Shields, Beverley M.
    Nyirenda, Moffat J.
    Jones, Angus G.
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (02)
  • [33] Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
    Buse, John B.
    Bode, Bruce W.
    Mertens, Ann
    Cho, Young Min
    Christiansen, Erik
    Hertz, Christin L.
    Nielsen, Morten A.
    Pieber, Thomas R.
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (02)
  • [34] Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study
    Nagai, Yoshio
    Nishine, Ami
    Hashimoto, Eriko
    Nakayama, Taiga
    Sasaki, Yosuke
    Murakami, Mariko
    Ishii, Satoshi
    Kato, Hiroyuki
    Tanaka, Yasushi
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 567 - 572
  • [35] Effects of physician's diabetes self-management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self-monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, open-labeled, prospective randomized clinical trial
    Tanaka, Nagaaki
    Yabe, Daisuke
    Murotani, Kenta
    Yamaguchi, Yuko
    Fujita, Yuki
    Kubota, Sodai
    Nakashima-Yasuda, Rena
    Kubota-Okamoto, Saki
    Ueno, Shinji
    Yamazaki, Yuji
    Kuwata, Hitoshi
    Watanabe, Koin
    Hyo, Takanori
    Hamamoto, Yoshiyuki
    Kurose, Takeshi
    Higashiyama, Hiroko
    Seino, Yusuke
    Yamada, Yuichiro
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (12) : 2221 - 2231
  • [36] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    Buse, John B.
    Klonoff, David C.
    Nielsen, Loretta L.
    Guan, Xuesong
    Bowlus, Christopher L.
    Holcombe, John H.
    Maggs, David G.
    Wintle, Matthew E.
    CLINICAL THERAPEUTICS, 2007, 29 (01) : 139 - 153
  • [37] Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study
    Fisher, George A., Jr.
    Wolin, Edward M.
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Mirakhur, Beloo
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    ONCOLOGIST, 2018, 23 (01) : 16 - 24
  • [38] Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study
    DeSalvo, Daniel J.
    Noor, Nudrat
    Xie, Cicilyn
    Corathers, Sarah D.
    Majidi, Shideh
    McDonough, Ryan J.
    Polsky, Sarit
    Izquierdo, Roberto
    Rioles, Nicole
    Weinstock, Ruth
    Obrynba, Kathryn
    Roberts, Alissa
    Vendrame, Francesco
    Sanchez, Janine
    Ebekozien, Osagie
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (02): : 322 - 328
  • [39] Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease
    Ruiz de Adana, Maria S.
    Colomo, Natalia
    Maldonado-Araque, Cristina
    Fontalba, Maria I.
    Linares, Francisca
    Garcia-Torres, Francisca
    Fernandez, Rosario
    Bautista, Carmen
    Olveira, Gabriel
    de la Cruz, Jose L.
    Rojo-Martinez, Gemma
    Valdes, Sergio
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (02) : 158 - 165
  • [40] A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study
    Guo, Lixin
    Chen, Li
    Chang, Baocheng
    Yang, Liyong
    Liu, Yu
    Feng, Bo
    DIABETES OBESITY & METABOLISM, 2018, 20 (12) : 2740 - 2747